Increased serum 90K and Galectin-3 expression are associated with advanced stage and a worse prognosis in diffuse large B-cell lymphomas.
The role of 90K and galectin-3 in cell-to-extracellular matrix adhesion and tumor metastasis has been reported, but little is known about their role in the prognosis and extranodal involvement of diffuse large B-cell lymphomas (DLBCL). Thus, we measured serum 90K concentration by enzyme-linked immunosorbent assay and tissue expression of galectin-3 by immunohistochemistry in newly diagnosed DLBCL patients. The mean serum 90K concentration was higher in DLBCL than in healthy controls (1,408.81 +/- 89.45 vs. 980.94 +/- 58.69 ng/ml, p = 0.036). High serum 90K (median value >or=1,249.50 ng/ml) and high galectin-3 expression (grade 3 positive staining in >75% of cells) showed a significant association with stage III/IV, >or=2 extranodal involvements and risk of high/high-intermediate international prognostic index (p < 0.05). The complete response (CR) rate (86.9%, 20/23) in the low 90K group was higher than in the high 90K group (56.5%, 13/23). Among 14 patients with high galectin-3 expression, only 6 patients showed CR (42.9%). The time to progression and overall survival were shorter in the group with high 90K and galectin-3 expression (p < 0.05). In conclusion, serum 90K and galectin-3 expression might be useful markers to indicate the extent of lymphoma involvement and prognosis in DLBCL.
Kim
Seok Jin
SJ
Department of Medicine, Division of Hematology-Oncology, Sungkyunkwan University School of Medicine, Seoul, Korea.
Lee
Seung Jin
SJ
Sung
Hwa Jung
HJ
Choi
In Keun
IK
Choi
Chul Won
CW
Kim
Byung Soo
BS
Kim
Jun Suk
JS
Yu
Woosung
W
Hwang
Hee Sang
HS
Kim
In Sun
IS
D000951:Antigens, Neoplasm / Q000097:blood*; D014408:Biomarkers, Tumor; D005260:Female; D037502:Galectin 3 / Q000096:biosynthesis* / Q000097:blood; D015870:Gene Expression; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood* / Q000473:pathology*; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood*; D008875:Middle Aged; D011379:Prognosis; D016896:Treatment Outcome
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D037502:Galectin 3; D008562:Membrane Glycoproteins; C114782:TAA90K protein, human